Combination Trial in ALS - Actively enrolling
Modafinil for fatigue in ALS - Actively enrolling
Nutrition in ALS - Actively enrolling
Genetic and Epidemiology - Actively enrolling
DNA Banking - Actively enrolling
Preliminary Study of ALS Oxidative Stress - Actively enrolling
Aeolus - Enrollment pending
Minocycline in ALS– Enrollment completed
Clinical Trial of High Dose CoQ10 in ALS - Enrollment completed

Please call Jackie Montes at 212-305-3632 for more information.

The New York State Psychiatric Institute and the Eleanor and Lou Gehrig MDA/ALS Research Center are now recruiting for a clinical trial of Modafinil(Provigil) for the treatment of fatigue in ALS.

Q: What is modafinil?
A: Modafinil is an FDA approved medication to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy. It is now being studied for it’s effects on fatigue in other conditions.

Q: What are the enrollment requirements?
A: Eligible participants will have:
• Presence of significant fatigue
• Forced Vital Capacity (FVC – a respiratory test) > 50%
• Ability to swallow capsules
• No major depressive disorder

Q: Who can I contact for information?
A: Judith Rabkin, Ph.D
(jgr1@columbia.edu, or call 212-543-5762)
or
Martin McElhiney, Ph.D
(mcelhin@pi.cpmc.columbia.edu, or call 212-543-5331)